FDA Approves First Drug to Treat Group of Rare Blood Disorders in Nearly 14 Years

SILVER SPRING, Md., Sept. 25, 2020 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another......
. .
Veröffentlicht von: Finanzen.at - Nachrichten Ticker - Saturday, 26 September

Share |